Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.65 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.65 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.65 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.65 |
| ▸ | FAAH | O00519 | 3/20 | 0.62 |
| ▸ | DGKA | P23743 | 1/20 | 0.61 |
| ▸ | MGLL | Q99685 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | CNR2 | P34972 | 1/20 | 0.59 |
| ▸ | SELP | P16109 | 1/20 | 0.57 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL1715383 | 0.96 | PRKCA (0.70) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| Ethylene Glycol SCHEMBL93687 | 0.96 | PRKCA (0.70) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL8713181 | 0.95 | FAAH (0.64) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL8705133 | 0.95 | FAAH (0.64) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL8705907 | 0.95 | FAAH (0.64) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL8713189 | 0.95 | FAAH (0.64) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL8716198 | 0.94 | FAAH (0.66) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL8703026 | 0.94 | FAAH (0.66) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL8716201 | 0.94 | FAAH (0.66) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL8706985 | 0.94 | FAAH (0.66) | PRKCAPRKCEPRKCQPRKCDFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250318963-A1 | ABSORBENT ARTICLES AND METHODS OF MANUFACTURING THE SAME | BANK OF AMERICA, N.A., AS COLLATERAL AGENT | 2025-10-16 | — | — | US | claimed |
| EP-4486289-A1 | COMPOSITIONS AND METHODS FOR CURLY HAIR | L'OREAL (FR) | 2025-01-08 | — | — | EP | claimed |
| WO-2023164280-A1 | COMPOSITIONS AND METHODS FOR CURLY HAIR | RUGHANI RONAK (US) | 2023-08-31 | — | — | WO | claimed |
| CN-111432805-B | Pharmaceutical formulations of 3 alpha-ethynyl-3 beta-hydroxyandrostan-17-one oxime | 梅克里内科尼蒂翁公司 | 2023-02-17 | — | — | CN | claimed |
| CN-113321449-B | Manufacturing process of silicon PU for plastic track | 湖北菲客体育产业集团有限公司 | 2022-03-29 | — | — | CN | claimed |
| US-11123351-B2 | Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime | UMECRINE COGNITION AB (SE) | 2021-09-21 | — | — | US | claimed |
| CN-113321449-A | Manufacturing process of silicon PU for plastic track | 湖北菲客体育产业集团有限公司 | 2021-08-31 | — | — | CN | claimed |
| EP-3716954-A1 | PHARMACEUTICAL FORMULATION OF 3 -ETHYNYL-3 -HYDROXYANDROSTAN-17-ONE OXIME | Umecrine Cognition AB (SE) | 2020-10-07 | — | — | EP | claimed |
| US-20200297737-A1 | PHARMACEUTICAL FORMULATION OF 3-ALPHA-ETHYNYL-3-BETA-HYDROXYANDROSTAN-17-ONE OXIME | UMECRINE COGNITION AB (SE) | 2020-09-24 | — | — | US | claimed |
| CN-111432805-A | Pharmaceutical formulations of 3 α -ethynyl-3 β -hydroxyandrostan-17-one oxime | 梅克里内科尼蒂翁公司 | 2020-07-17 | — | — | CN | claimed |
| WO-2019102040-A1 | PHARMACEUTICAL FORMULATION OF 3α-ETHYNYL-3β-HYDROXYANDROSTAN-17-ONE OXIME | UMECRINE COGNITION AB (SE) | 2019-05-31 | — | — | WO | claimed |
| WO-2026107233-A2 | COMPOSITIONS, SYSTEMS, AND METHODS FOR INCREASING NITRIC OXIDE IN A SUBJECT | LifeActive, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260137613-A1 | MANUFACTURE, ISOLATION, PURIFICATION, AND USES OF SMALL PARTICLE SIZE CELLULOSE PARTICLES AND COMPOSITIONS | RENMATIX INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12558303-B2 | Manufacture, isolation, purification, and uses of small particle size cellulose particles and compositions | RENMATIX, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4681783-A2 | MANUFACTURE, ISOLATION, PURIFICATION, AND USES OF SMALL PARTICLE SIZE CELLULOSE PARTICLES AND COMPOSITIONS | Renmatix Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-1141111-A1 | GEL COMPOSITIONS | Penreco (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001007009-A1 | LYSINE OXIDASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001006829-A2 | LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2000064408-A1 | WET WIPES HAVING SKIN HEALTH BENEFITS | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2000-11-02 | — | — | WO | disclosed |
| WO-2000026285-A1 | GEL COMPOSITIONS | PENRECO (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297737-A1 | PHARMACEUTICAL FORMULATION OF 3-ALPHA-ETHYNYL-3-BETA-HYDROXYANDROSTAN-17-ONE OXIME | HSD3B1, HSD3B2, HSD17B1 | PRKCA 3396/4885PRKCE 2408/4885PRKCQ 3250/4885 |
| US-11123351-B2 | Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime | HSD3B1, HSD3B2, HSD17B1 | PRKCA 3396/4885PRKCE 2408/4885PRKCQ 3250/4885 |
| US-12558303-B2 | Manufacture, isolation, purification, and uses of small particle size cellulose particles and compositions | CUTA, COL2A1, SAMM50 | PRKCA 534/4885PRKCE 231/4885PRKCQ 623/4885 |
| US-20260137613-A1 | MANUFACTURE, ISOLATION, PURIFICATION, AND USES OF SMALL PARTICLE SIZE CELLULOSE PARTICLES AND COMPOSITIONS | CUTA, COL2A1, COL1A1 | PRKCA 1097/4885PRKCE 544/4885PRKCQ 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.